Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.
Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.
Immunotherapy led to better outcomes for patients with inoperable non-small-cell lung cancer.
Targeted therapy reduced risk of disease progression or death by about 50 percent.
Communities focused on specific lung cancer genetic mutations offer patient support and accelerate research.
Immunotherapy combo reduced the risk of disease progression or death in a Phase III study.
A research dog identified cancerous lung tumors 97 percent of the time.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.